Despite the increasing availability of gene sequencing, several barriers prevent it from having utility as a tool for diagnosis of type 1 von Willebrand disease.
Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma.
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
Although gray zone lymphoma has distinct morphologic features, immunophenotyping can make classifying gray zone lymphoma challenging.
Although the 7 + 3 regimen has been the standard of care for acute myeloid leukemia for decades, it may be time to reassess its value and utility.